drugset / Trial / NCT00061620
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest dose of Tezacitabine (FMdC) which can be safely given as a continuous infusion by vein to patients with hematologic malignancies. The general safety and effectiveness of this drug will also be studied.
Timeline
- Start
- 2001-09-06
- Primary completion
- 2004-02-12
- Completion
- 2004-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TEZACITABINE ANHYDROUS | Other / unclassified | 7.5 mg/m2 | Intravenous |